Budesonide/formoterol combination in COPD: a US perspective (Q37805343)

23 August 2017

4 references

2 October 2019

7 November 2019

13 November 2019

17 November 2019

Budesonide/formoterol combination in COPD: a US perspective (English)

1 reference

chronic obstructive pulmonary disease

23 August 2017

4 references

2 October 2019

7 November 2019

13 November 2019

17 November 2019

1 reference

2 October 2019

1 reference

7 November 2019

1 reference

7 November 2019

1 reference

13 November 2019

1 reference

17 November 2019

budesonide/formoterol

1 reference

5

Nicola A Hanania

1 reference

23 August 2017

Amir Sharafkhaneh

1

1 reference

23 August 2017

Amarbir S Mattewal

series ordinal

2

1 reference

23 August 2017

Vinu M Abraham

series ordinal

3

1 reference

23 August 2017

Goutham Dronavalli

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

5 October 2010

5 references

International Journal of Chronic Obstructive Pulmonary Disease

23 August 2017

2 October 2019

7 November 2019

13 November 2019

17 November 2019

5 references

23 August 2017

2 October 2019

7 November 2019

13 November 2019

17 November 2019

5

1 reference

23 August 2017

357-366

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

23 August 2017

start time

1 October 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Symbicort: a pharmacoeconomic review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Optimizing economic outcomes in the management of COPD.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

The nature of small-airway obstruction in chronic obstructive pulmonary disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Long-acting beta2-agonists: comparative pharmacology and clinical outcomes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Pharmacological similarities and differences between beta2-agonists

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Anti-inflammatory actions of steroids: molecular mechanisms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Molecular mechanisms of glucocorticoid action in asthma

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Site and Nature of Airway Obstruction in Chronic Obstructive Lung Disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2962302

Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids

1 September 2018

1 reference

12 December 2020

Pulmonary disposition of the potent glucocorticoid budesonide, evaluated in an isolated perfused rat lung model

1 reference

12 December 2020

Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung

1 reference

12 December 2020

Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients

1 reference

12 December 2020

Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer

1 reference

12 December 2020

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study

1 reference

12 December 2020

The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma

1 reference

12 December 2020

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

12 December 2020

Chronic obstructive pulmonary disease surveillance--United States, 1971-2000

1 reference

12 December 2020

Identifiers

DOI

10.2147/COPD.S4215

1 reference

23 August 2017

1 reference

23 August 2017

1 reference